Viking Therapeutics Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.77 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $32.60Price as of 30 Sep 2026 Data confidenceNot applicable Market Cap $4.1B Enterprise Value $4B Shares Outstanding 116.5M diluted Next Earnings Date28 Oct 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Viking Therapeutics represents a high-conviction, clinical-stage biopharmaceutical opportunity focused on the multi-billion dollar obesity and metabolic disorder markets. The investment thesis is anchored by its lead asset, VK2735, a dual GLP-1/GIP receptor agonist showing best-in-class potential in both subcutaneous and oral formulations. With a robust, debt-free balance sheet holding over $600 million in cash, Viking is fully funded to advance its Phase III VANQUISH trials. While competing against established giants, Viking's strong clinical efficacy, superior tolerability profile, and potential as an attractive acquisition target provide asymmetric upside for investors. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$35.00 Mean target$92.39 High · most bullish analyst$125.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $34.00 VK2735 encounters unexpected safety or tolerability issues during Phase III trials, leading to clinical delays or FDA rejection. High R&D burn rates deplete cash reserves faster than anticipated, forcing highly dilutive equity raises. Competitors Eli Lilly and Novo Nordisk lock up the market, leaving little room for a late-stage clinical entrant. Base CaseCentral scenario $92.39 Matches the consensus meanVK2735 successfully completes Phase III trials with competitive efficacy and safety profiles, matching or slightly exceeding current market blockbusters. The company successfully initiates and progresses its oral Phase III program. Viking remains independent, securing a strategic commercialization partnership or establishing a niche commercial footprint in the obesity and MASH markets. Bull CaseUpside scenario $125.00 VK2735 demonstrates superior weight loss efficacy and class-leading tolerability in Phase III trials, leading to rapid FDA approval. The oral formulation establishes itself as the preferred maintenance therapy, capturing a significant share of the projected $100B+ global obesity market. Additionally, Viking becomes a prime acquisition target for a major pharmaceutical company looking to enter or expand its presence in the metabolic space. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |